Table 5 Stratification of Best response based on type of Immunotherapy (PR = Partial Response, CR = Complete Response, SD = Stable Disease, PD = Progressive Disease, ORR = Objective Response Rate, DCR = Disease Control Rate)
Anti-PD-1 | No Metformin N = 20 (60.6%) | Metformin N = 14 (63.6%) |  |
|---|---|---|---|
Best Response | |||
 PR | 8 (40%) | 7 (50%) | P = 0.6 |
 CR | 3 (15%) | 3 (21.4%) | |
 SD | 2 (10%) | 2 (14.3%) | |
 PD | 7 (35%) | 2 (14.3%) | |
ORR | 55% | 71.4% | P = 0.33 |
DCR | 65% | 85.7% | P = 0.17 |
Median time to achieve best response (Months) | 2.8 | 2.8 | P = 0.28 |
Ipilimumab/Nivolumab | No Metformin N = 9 (27.3%) | Metformin N = 6 (27.3%) |  |
Best Response | |||
 PR | 6 (66.7%) | 1 (16.7) | P = 0.16 |
 CR | 1 (11.1%) | 2 (33.3%) | |
 SD | 0 (0%) | 0 (0%) | |
 PD | 2 (22.2%) | 3 (50%) | |
ORR | 77.7% | 50% | P = 0.26 |
DCR | 77.7% | 50% | P = 0.26 |
Median time to achieve best response (Months) | 2.5 | 2.8 | P = 0.9 |